322 related articles for article (PubMed ID: 19795581)
21. Targeted therapy in non-small-cell lung cancer.
Herbst RS
Oncology (Williston Park); 2002 Sep; 16(9 Suppl 9):19-24. PubMed ID: 12375797
[TBL] [Abstract][Full Text] [Related]
22. Cetuximab as a single agent or in combination with chemotherapy in lung cancer.
Kim ES
Clin Lung Cancer; 2004 Dec; 6 Suppl 2():S80-4. PubMed ID: 15638964
[TBL] [Abstract][Full Text] [Related]
23. Novel agents in the treatment of non-small cell lung cancer: implications for neoadjuvant chemotherapy?
Bergqvist M; Henriksson R; Brattström D
In Vivo; 2005; 19(3):523-33. PubMed ID: 15875771
[TBL] [Abstract][Full Text] [Related]
24. [Target population and predictive factors of survival and efficacy of anti-HER1/EGFR drugs].
Cadranel J
Rev Pneumol Clin; 2007 Jan; 63(1 Pt 2):2S10-1. PubMed ID: 17242637
[No Abstract] [Full Text] [Related]
25. Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier.
Sangha R; Lara PN; Mack PC; Gandara DR
Curr Opin Oncol; 2009 Mar; 21(2):116-23. PubMed ID: 19532012
[TBL] [Abstract][Full Text] [Related]
26. Targeted lung cancer therapies.
Farmer G
Nat Rev Drug Discov; 2004 Jul; 3(7):547-8. PubMed ID: 15272497
[No Abstract] [Full Text] [Related]
27. [Biological therapy in non-small-cell lung cancer (NSCLC)].
Souquet PJ
Rev Pneumol Clin; 2004 Nov; 60(5 Pt 3):4S53-4S56. PubMed ID: 15687996
[No Abstract] [Full Text] [Related]
28. Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24+ non-small cell lung cancer patients.
Shomura H; Shichijo S; Komatsu N; Matsueda S; Mine T; Rikimaru T; Sato Y; Todo S; Itoh K
Eur J Cancer; 2004 Jul; 40(11):1776-86. PubMed ID: 15251169
[TBL] [Abstract][Full Text] [Related]
29. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
Burris HA
Oncogene; 2009 Aug; 28 Suppl 1():S4-13. PubMed ID: 19680296
[TBL] [Abstract][Full Text] [Related]
30. Potential for molecularly targeted therapy against epidermal growth factor receptor ligands.
Miyamoto S; Fukami T; Yagi H; Kuroki M; Yotsumoto F
Anticancer Res; 2009 Mar; 29(3):823-30. PubMed ID: 19414315
[TBL] [Abstract][Full Text] [Related]
31. Developing targeted therapies for lung cancer.
Gandara DR
Clin Adv Hematol Oncol; 2003 Nov; 1(11):648-9, 690. PubMed ID: 16258461
[No Abstract] [Full Text] [Related]
32. Cetuximab: potential role as first-line treatment for advanced non-small cell lung cancer.
Pirker R
Clin Adv Hematol Oncol; 2008 Oct; 6(10):735-6. PubMed ID: 18997663
[No Abstract] [Full Text] [Related]
33. The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC.
Hirsch FR
Oncogene; 2009 Aug; 28 Suppl 1():S1-3. PubMed ID: 19680291
[TBL] [Abstract][Full Text] [Related]
34. New treatment strategies in patients with advanced non-small-cell lung cancer and performance status 2.
Rodriguez E; Lilenbaum RC
Clin Lung Cancer; 2008 Nov; 9(6):326-30. PubMed ID: 19073514
[TBL] [Abstract][Full Text] [Related]
35. A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activity in vivo.
Adams TE; Koziolek EJ; Hoyne PH; Bentley JD; Lu L; Lovrecz G; Ward CW; Lee FT; Scott AM; Nash AD; Rothacker J; Nice EC; Burgess AW; Johns TG
Growth Factors; 2009 Jun; 27(3):141-54. PubMed ID: 19333814
[TBL] [Abstract][Full Text] [Related]
36. Targeting the epidermal growth factor receptor a new strategy in cancer treatment.
Gianni L; Grasselli G
Suppl Tumori; 2002; 1(4):S60-1. PubMed ID: 12415824
[No Abstract] [Full Text] [Related]
37. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status.
Pesek M; Benesova L; Belsanova B; Mukensnabl P; Bruha F; Minarik M
Anticancer Res; 2009 Jul; 29(7):2767-73. PubMed ID: 19596959
[TBL] [Abstract][Full Text] [Related]
38. Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?
Agarwal V; Lind MJ; Cawkwell L
Cancer Treat Rev; 2011 Nov; 37(7):533-42. PubMed ID: 21183281
[TBL] [Abstract][Full Text] [Related]
39. Multitargeted inhibitors in lung cancer: new clinical data.
Bar J; Herbst RS; Onn A
Clin Lung Cancer; 2008; 9 Suppl 3():S92-9. PubMed ID: 19419930
[TBL] [Abstract][Full Text] [Related]
40. The development of HKI-272 and related compounds for the treatment of cancer.
Wissner A; Mansour TS
Arch Pharm (Weinheim); 2008 Aug; 341(8):465-77. PubMed ID: 18493974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
